Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 18/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.61 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076457 | 0.90 | PDGFRB (0.68) | PDGFRBNTRK1KCNH2NTRK2NTRK3 | |
| SCHEMBL4076458 | 0.90 | NTRK1 (0.75) | PDGFRBNTRK1KCNH2NTRK2NTRK3 | |
| SCHEMBL4078771 | 0.89 | PDGFRB (0.69) | PDGFRBNTRK1KCNH2NTRK2NTRK3 | |
| SCHEMBL4081122 | 0.88 | PDGFRB (0.76) | PDGFRBNTRK1KCNH2NTRK2NTRK3 | |
| SCHEMBL4076443 | 0.86 | NTRK1 (0.64) | PDGFRBNTRK1KCNH2NTRK2NTRK3 | |
| SCHEMBL4089660 | 0.86 | NTRK1 (0.56) | PDGFRBNTRK1KCNH2NTRK2NTRK3 | |
| SCHEMBL4083225 | 0.85 | PDGFRB (0.60) | PDGFRBNTRK1KCNH2NTRK2NTRK3 | |
| SCHEMBL4086148 | 0.85 | NTRK1 (0.67) | PDGFRBNTRK1KCNH2NTRK2NTRK3 | |
| SCHEMBL4080523 | 0.85 | NTRK1 (0.66) | PDGFRBNTRK1KCNH2NTRK2NTRK3 | |
| SCHEMBL4080111 | 0.85 | NTRK1 (0.64) | PDGFRBNTRK1KCNH2NTRK2NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773836-B1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PROD INC (US) | 2012-09-05 | — | — | EP | claimed |
| US-7595325-B2 | Substituted pyrrolo[2,3-d]pyrimidine derivatives useful in cancer treatment | PFIZER INC. (US) | 2009-09-29 | — | — | US | claimed |
| EP-1773836-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | Pfizer Products Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | PFIZER INC | 2006-02-16 | — | — | US | claimed |
| WO-2005116035-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | claimed |
| EP-1773836-B1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PROD INC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-7595325-B2 | Substituted pyrrolo[2,3-d]pyrimidine derivatives useful in cancer treatment | PFIZER INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1773836-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | Pfizer Products Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | PFIZER INC | 2006-02-16 | — | — | US | disclosed |
| WO-2005116035-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | TP53, DPYD, CCNT1 | PDGFRB 2700/4885NTRK1 3916/4885KCNH2 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.